Sirtlab, an innovative Israeli start-up is on the verge of redefining ageing – and extending human life by up to 30%.
“SIRT-6 doesn’t just help us live longer—it helps us live better,” says Prof. Haim Cohen, founder and chief scientist at Sirtlab and head of Bar-Ilan’s Sagol Center for Healthy Aging.
“We’ve managed to elevate SIRT-6 levels in older test subjects to those typically seen in much younger individuals, and the effects are stunning.”
According to Cohen, the increased activity of SIRT-6 has been linked to improved memory, better liver function, and even hair regrowth.
“In our studies, older animals with enhanced SIRT-6 activity performed as well as their younger counterparts, physically and cognitively.”
The treatment is currently one step away from human trials. So far, results in animals have been promising: older subjects not only lived longer but showed energy levels, physical performance, and bodily functions similar to the young.
“We’re hopeful this translates to humans,” says Prof. Eitan Friedman, director of Oncogenetics at Assuta Medical Center. “If the upcoming clinical trials confirm these results, this could be a true game-changer. I’m cautiously optimistic.”
Sirtlab has already raised millions of dollars and plans to raise more via the investment platform PeopleBiz, accelerating the development process. CEO Boaz Mashuoli emphasizes the global importance of the research: “We believe this treatment could significantly contribute to the future of human health. But first, we need to complete additional safety testing in animals before moving on to clinical trials.”
If all goes according to plan, human trials will begin in about 18 months, with the drug potentially hitting the Israeli market within three years.
“This drug isn’t about immortality,” explains Dr. Hagit Ashush, Vice President of R&D at Sirtlab. “It’s about delaying the onset of age-related diseases and improving quality of life in later years. Our goal is to slow ageing itself.”
